{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:28:44Z","timestamp":1790735324481,"version":"4.1.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec id=\"ab-doi230043-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Because of a paucity of qualitative research on prurigo nodularis (PN), the symptoms and impacts of PN that are most important to patients are poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230043-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore patients\u2019 perspectives on their PN symptoms and to understand the impacts of the condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230043-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>One-on-one qualitative telephone interviews were held with English-speaking US adults aged 18 years or older with a confirmed diagnosis of PN, severe pruritus, and moderate to severe sleep disturbance. Participants were recruited via patient associations, patient panels, and social media posts. Interviews took place between September 10, 2020, and March 16, 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230043-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The main symptoms of PN and their impacts on quality of life were identified by content analysis of deidentified interview transcripts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230043-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 21 adults with PN (mean [SD] age, 53.1 [11.8] years; 15 [71%] female; 2 African American or Black patients [10%], 1 Asian patient [5%], and 18 White patients [86%]; of these, 1 patient [ 5%] had Hispanic or Latino ethnicity) participated in the interviews. All participants reported itch, pain associated with PN, bleeding or scabbing, and dry skin. Other frequently reported symptoms included lumps or bumps (95%), having a crust on the skin (95%), burning (90%), stinging (90%), lesions or sores (86%), skin discoloration (86%), and raw skin (81%). Of the 17 participants who indicated what their worst symptoms were, 15 (88%) identified itching as the worst or 1 of the worst symptoms. The most frequently reported impacts of PN for quality of life were changes in sleep (100%), daily life (100%), feelings or mood (95%), relationships (95%), social life (81%), and work or school (71%). Overall, the worst impact of PN was its association with impaired feelings or mood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi230043-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This qualitative study suggests the importance of itching, sleep disturbance, and other symptoms and impacts of PN. This information can be used to guide end point selection in clinical trials and to inform patient-centric decision-making in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.3251","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T11:12:58Z","timestamp":1695208378000},"page":"1205","source":"Crossref","is-referenced-by-count":25,"title":["Patient Perspectives on Living With Severe Prurigo Nodularis"],"prefix":"10.1001","volume":"159","author":[{"given":"Danielle","family":"Rodriguez","sequence":"first","affiliation":[{"name":"Evidera, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Dias-Barbosa","sequence":"additional","affiliation":[{"name":"Evidera, Ivry-sur-Seine, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanyang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Evidera, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarif K.","family":"Jabbar Lopez","sequence":"additional","affiliation":[{"name":"Galderma, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[{"name":"Galderma, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Puelles","sequence":"additional","affiliation":[{"name":"Galderma, Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"doi230043r1","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.2018.32.issue-7","article-title":"European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi230043r2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMe1916733","article-title":"Breaking the itch-scratch cycle in prurigo nodularis.","volume":"382","author":"Kwatra","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"doi230043r3","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi230043r5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management.","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230043r6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jaad.2019.09.007","article-title":"Analysis of real-world treatment patterns in patients with prurigo nodularis.","volume":"82","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi230043r7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/09546634.2019.1707469","article-title":"Emerging novel therapeutic agents for the treatment of patients with prurigo nodularis.","volume":"32","author":"Maredia","year":"2021","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"doi230043r8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"doi230043r9","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s13555-022-00782-2","article-title":"Prurigo nodularis: a review of IL-31RA blockade and other potential treatments.","volume":"12","author":"Bewley","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"doi230043r10","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.2018.32.issue-12","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi230043r11","first-page":"5","article-title":"Prurigo nodularis: review and emerging treatments.","volume":"26","author":"Leis","year":"2021","journal-title":"Skin Therapy Lett"},{"issue":"3","key":"doi230043r12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","article-title":"A systematic review of evidence-based treatments for prurigo nodularis.","volume":"80","author":"Qureshi","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"doi230043r13","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1111\/ced.v46.7","article-title":"Clinical characteristics and disease burden in prurigo nodularis.","volume":"46","author":"Aggarwal","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"doi230043r14","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","article-title":"Health-related quality of life and economic burden of prurigo nodularis.","volume":"86","author":"Whang","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi230043r15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.","volume":"79","author":"Steinke","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi230043r17","doi-asserted-by":"publisher","first-page":"e815","DOI":"10.1111\/jdv.v34.12","article-title":"The impact of prurigo nodularis on sleep disturbance and related impact: a systematic review.","volume":"34","author":"Gwillim","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"doi230043r18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/jdv.v34.10","article-title":"Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study.","volume":"34","author":"Pereira","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"doi230043r19","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3471","article-title":"Treatment and burden of disease in a cohort of patients with prurigo nodularis: a survey-based study.","volume":"100","author":"Todberg","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"doi230043r20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3778","article-title":"Impact of itch on sleep disturbance in patients with prurigo nodularis.","volume":"101","author":"Gwillim","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"doi230043r21","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1111\/jdv.2017.31.issue-2","article-title":"Anxiety, depression and suicide in patients with prurigo nodularis.","volume":"31","author":"J\u00f8rgensen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"doi230043r22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.2019.33.issue-1","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.","volume":"33","author":"Brenaut","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi230043r23","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases.","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi230043r24","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjd.v181.4","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"issue":"2","key":"doi230043r25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/bjd.v186.2","article-title":"Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.","volume":"186","author":"Puelles","year":"2022","journal-title":"Br J Dermatol"},{"issue":"9","key":"doi230043r26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","article-title":"Standards for reporting qualitative research: a synthesis of recommendations.","volume":"89","author":"O\u2019Brien","year":"2014","journal-title":"Acad Med"},{"issue":"8","key":"doi230043r27","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 1\u2014eliciting concepts for a new PRO instrument.","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"issue":"8","key":"doi230043r28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding.","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"issue":"3","key":"doi230043r31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1159\/000437206","article-title":"Health-related quality of life in chronic pruritus: an analysis related to disease etiology, clinical skin conditions and itch intensity.","volume":"231","author":"Warlich","year":"2015","journal-title":"Dermatology"},{"issue":"4","key":"doi230043r32","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients.","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"doi230043r4"},{"key":"doi230043r16","author":"Fofana","year":"2020"},{"key":"doi230043r29","unstructured":"Food and Drug Administation. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. Updated April 6, 2023. Accessed October 12, 2022. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical"},{"key":"doi230043r30","unstructured":"Food and Drug Administration. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Updated June 30, 2022. Accessed October 12, 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2809349\/jamadermatology_rodriguez_2023_oi_230043_1699989200.96727.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T11:02:59Z","timestamp":1700046179000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2809349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.3251","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}